Advertisement
Advertisement
U.S. markets close in 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.58-0.21 (-2.70%)
As of 03:19PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close7.79
Open7.87
Bid7.58 x 1000
Ask7.59 x 800
Day's Range7.49 - 7.90
52 Week Range2.87 - 11.70
Volume1,294,028
Avg. Volume5,828,201
Market Cap628.458M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-10.43
Earnings DateNov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLUE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • bluebird bio, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    20 hours agoMorningstar
View more
Advertisement
Advertisement